XML 79 R60.htm IDEA: XBRL DOCUMENT
v3.25.1

Moderna Collaboration and License Agreement - Narrative (Details) $ in Thousands | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Jan. 31, 2025 USD ($) | Sep. 30, 2024 target | Jun. 30, 2024 USD ($) | Jan. 31, 2022 USD ($) target product | Dec. 31, 2024 USD ($) target obligation | Dec. 31, 2023 USD ($) | Feb. 28, 2025 target | Dec. 31, 2022 USD ($)
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | $ 19,600 | $ 14,900 |  |
Deferred revenue liability |  |  |  |  | 44,979 | 46,413 |  | $ 47,459
Collaboration revenues |  |  |  |  | 19,632 | $ 14,919 |  |
Option Right Collaboration Revenues |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | 3,800 |  |  |
Milestones |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | 2,000 |  |  |
Moderna |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Collaboration receivable |  |  |  |  | $ 2,900 |  |  |
Moderna | Subsequent Event |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Proceeds from collection of collaboration receivable | $ 2,900 |  |  |  |  |  |  |
Collaboration and License Agreement |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Number of potential research target designations | target |  |  |  |  | 12 |  |  |
Collaboration and License Agreement | Research and Development Services |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Variable consideration |  |  |  |  | $ 73,900 |  |  |
Term of contract (in years) |  |  |  |  | 5 years |  |  |
Noncurrent portion of deferred revenue |  |  |  |  | $ 41,300 |  |  |
Collaboration and License Agreement | Moderna |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Maximum of research targets | target |  |  |  | 12 |  |  |  |
Number of nominated autoimmune target | target |  | 2 |  |  |  |  |  |
Collaboration and License Agreement | Moderna | Subsequent Event |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Number of oncology research targets | target |  |  |  |  |  |  | 12 |
Collaboration and License Agreement | Moderna | Research and Development Services |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Upfront non-refundable payment received |  |  |  | $ 45,000 | $ 45,000 |  |  |
Number of potential products to develop and commercialize | product |  |  |  | 12 |  |  |  |
Minimum commitment to reimburse research and development costs |  |  |  | $ 10,000 |  |  |  |
Period of reimbursement of research and development costs (in years) |  |  |  | 3 years |  |  |  |
Number of performance obligations | obligation |  |  |  |  | 2 |  |  |
Collaboration and License Agreement | Moderna | Minimum | Research and Development Services |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Amount receivable per product |  |  |  | $ 247,000 |  |  |  |
Collaboration and License Agreement | Moderna | Maximum | Research and Development Services |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Amount receivable per product |  |  |  | $ 253,000 |  |  |  |
Moderna License Agreement | Research and Development Services |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | $ 38,700 |  |  |
Moderna License Agreement | Moderna |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |
Milestone payment |  |  | $ 2,000 |  |  |  |  |
Collaboration revenues |  |  | $ 2,000 |  |  |  |  |
Deferred revenue liability |  |  |  |  | 45,000 |  |  |
Decrease in contract with customer, liability |  |  |  |  | $ 3,800 |  |  |

X
- Definition Amount receivable per product in development target designation, development, regulatory and commercial milestone payments. + References No definition available. + Details
Name: | carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights and Obligations, Milestone Payments + References No definition available. + Details
Name: | carm_CollaborativeArrangementRightsAndObligationsMilestonePayments
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period of contract. + References No definition available. + Details
Name: | carm_ContractTerm
Namespace Prefix: | carm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum number of research targets. + References No definition available. + Details
Name: | carm_MaximumNumberOfResearchTargets
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum commitment to reimburse research and development costs. + References No definition available. + Details
Name: | carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of Performance Obligations + References No definition available. + Details
Name: | carm_NumberOfPerformanceObligations
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of potential products to develop and commercialize + References No definition available. + Details
Name: | carm_NumberOfPotentialProductsToDevelopAndCommercialize
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Potential Research Target Designations + References No definition available. + Details
Name: | carm_NumberOfPotentialResearchTargetDesignations
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets, Gross, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsGrossOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Research Targets Nominated, Autoimmune + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsNominatedAutoimmune
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of reimbursement of research and development costs. + References No definition available. + Details
Name: | carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts
Namespace Prefix: | carm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront non-refundable payment received. + References No definition available. + Details
Name: | carm_UpfrontNonRefundablePaymentReceived
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of variable consideration. + References No definition available. + Details
Name: | carm_VariableConsideration
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_IncreaseDecreaseInContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_OtherReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash inflow from the collection of receivables classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromCollectionOfOtherReceivables
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=carm_MilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |